Librachrom (Sodium Cromoglicate)

Sodium cromoglicate stabilizes mast cells by blocking calcium influx required for degranulation. This prevents the release of histamine, prostaglandins, leukotrienes and other inflammatory mediators from conjunctival mast cells, thereby reducing the allergic and inflammatory response in the eye.

The dosing regimen for Librachrom is determined by the prescribing clinician based on the severity of the condition and patient factors. The prescriber will specify the number of drops, frequency and duration of therapy in the prescription.

Safety data for sodium cromoglicate in pregnancy and lactation are limited. Healthcare professionals should evaluate the potential benefits against any possible risks, and women who are pregnant or breastfeeding should discuss use with their physician before starting treatment.

To order Librachrom, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Librachrom (sodium cromoglicate) differs from antihistamine eye drops in that it stabilizes mast cells rather than blocking histamine receptors. This mechanism can provide broader control of inflammatory mediators, whereas antihistamines mainly relieve itching. Choice of therapy depends on clinical response, tolerance and physician preference.

Librachrom should be stored at ambient temperature, preferably below 25 °C, in its original container. Keep the bottle tightly closed, protect it from direct sunlight and moisture, and avoid freezing. Do not use the product after the expiry date printed on the label.

Librachrom is applied topically to the eye as directed by the prescriber. Typically, one or more drops are placed into the affected eye(s) using a clean fingertip to lower the bottle, avoiding contact with the ocular surface. Patients should wash their hands before and after administration.

Although rare, serious adverse events may include allergic contact dermatitis of the eyelid or peri‑ocular skin, severe ocular inflammation such as keratitis, corneal ulceration, or vision loss. Any sudden worsening of eye symptoms or signs of an allergic reaction should prompt immediate medical evaluation.

Librachrom should be avoided in individuals with known hypersensitivity to sodium cromoglicate or any excipients in the formulation. Patients with active ocular infections should defer use until the infection is resolved, and those wearing contact lenses should remove lenses before instillation.